Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:320

Official publication of the Indian Society of Nephrology
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (585 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

   Article Figures

 Article Access Statistics
    PDF Downloaded148    
    Comments [Add]    

Recommend this journal


  Table of Contents  
Year : 2015  |  Volume : 25  |  Issue : 1  |  Page : 62-63

S-amlodipine-induced gingival enlargement

Department of Nephrology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India

Date of Web Publication12-Jan-2015

Correspondence Address:
S Vikrant
Department of Nephrology, Indira Gandhi Medical College, Shimla - 171 001, Himachal Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-4065.144428

Rights and Permissions

How to cite this article:
Vikrant S. S-amlodipine-induced gingival enlargement. Indian J Nephrol 2015;25:62-3

How to cite this URL:
Vikrant S. S-amlodipine-induced gingival enlargement. Indian J Nephrol [serial online] 2015 [cited 2023 Feb 6];25:62-3. Available from:


S-amlodipine is the chirally pure, single, pharmacologically active enantiomer of amlodipine, a dihydropyridine calcium channel blocker. Compared to the racemic amlodipine, S-amlodipine has 1000-fold stronger affinity to the L-type calcium channels. [1] The use of racemic amlodipine is commonly associated with adverse events like peripheral edema headache, dizziness, flushing and abdominal pain, gingival overgrowth or enlargement. [2] Controlled clinical trials showed that S-amlodipine is rarely associated with these side effects. [1]

Gingival hyperplasia has potential cosmetic implications and provids new niches for the growth of microorganisms. Although the incidence of nifedipine-induced gingival hyperplasia is about 10%, there are few reports of amlodipine-related gingival hyperplasia. [3],[4],[5] We encountered two patients with this complication.

A 37-year-old man with a case of chronic kidney disease (CKD) stage III was on 5 mg daily dose of S-amlodipine for the past 1.5 years. He developed swelling of gums and was diagnosed S-amlodipine-induced gingival enlargement [Figure 1]a. S-amlodipine was substituted with metoprolol and moxonidine. Discontinuation of S-amlodipine and dental toileting led to resolution at 6 months [Figure 1]b.
Figure 1: (a) Gingival enlargement due to S - amlodipine and (b) resolution of the gingival enlargement at 6 months after discontinuation of the S - amlodipine; (c) gingival enlargement due to S - amlodipine and (d) resolution of the gingival enlargement at 6 months after discontinuation of the S-amlodipine

Click here to view

A 62-year-old woman with a case of CKD stage V was on 10 mg daily dose of S-amlodipine for 1 year. She developed swelling of gums, which used to bleed while eating or cleaning and was diagnosed with S-amlodipine-induced gingival enlargement [Figure 1]c. She refused dental treatment but S-amlodipine was changed to moxonidine. Six months later, she had regression of the gingival enlargement [Figure 1]d.

Phenytoin, calcium channel blockers and cyclosporine commonly cause gingival overgrowth. [3],[4],[5] Gingival overgrowth may be due to a direct effect of the drug that regresses upon interruption of drug therapy. [5] However, it is generally accepted that the inflammatory changes caused by the bacteria biofilm synergize with the drug effect to cause overgrowth of the soft tissues.

Treatment includes mechanical and chemical plaque (bacterial biofilm) control. Gingivectomy of the overgrown tissue is often needed. If the offending drug cannot be replaced, dental prophylaxes (dental cleaning) at 3-month intervals is recommended. [5]

  References Top

ASOMEX (S-amlodipine) Product Monograph. Pune, India: Emcure Pharmaceuticals Ltd.; 2006.  Back to cited text no. 1
Norvasc (amlodipine) Package Insert. New York: Pfizer Labs; 2013.  Back to cited text no. 2
Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663-4.  Back to cited text no. 3
Ellis JS, Seymour RA, Thomason JM, Monkman SC, Idle JR. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 1993;341:1102-3.  Back to cited text no. 4
Srivastava AK, Kundu D, Bandyopadhyay P, Pal AK. Management of amlodipine-induced gingival enlargement: Series of three cases. J Indian Soc Periodontol 2010;14:279-81.  Back to cited text no. 5
[PUBMED]  Medknow Journal  


  [Figure 1]


Print this article  Email this article


Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07